Head-To-Head Contrast: Emergent Biosolutions (NYSE:EBS) and Amylyx Pharmaceuticals (NASDAQ:AMLX)

Emergent Biosolutions (NYSE:EBS) and Amylyx Pharmaceuticals (NASDAQ:AMLX) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, dividends, institutional ownership, profitability, valuation, analyst recommendations and risk.

Analyst Recommendations

This is a summary of recent ratings and target prices for Emergent Biosolutions and Amylyx Pharmaceuticals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Emergent Biosolutions	2	1	3	0	2.17
Amylyx Pharmaceuticals	1	0	6	2	3.00

Emergent Biosolutions presently has a consensus price target of $10.00, indicating a potential upside of 69.41%. Amylyx Pharmaceuticals has a consensus price target of $43.71, indicating a potential upside of 46.40%. Given Emergent Biosolutions’ higher probable upside, research analysts plainly believe Emergent Biosolutions is more favorable than Amylyx Pharmaceuticals.

Valuation and Earnings

This table compares Emergent Biosolutions and Amylyx Pharmaceuticals”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Emergent Biosolutions	$742.90 million	0.41	$52.60 million	($5.10)	-1.16
Amylyx Pharmaceuticals	$87.37 million	43.94	-$144.74 million	($1.44)	-20.74

Emergent Biosolutions has higher revenue and earnings than Amylyx Pharmaceuticals. Amylyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Emergent Biosolutions, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Emergent Biosolutions has a beta of 2.37, meaning that its stock price is 137% more volatile than the S&P 500. Comparatively, Amylyx Pharmaceuticals has a beta of -0.09, meaning that its stock price is 109% less volatile than the S&P 500.

Profitability

This table compares Emergent Biosolutions and Amylyx Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Emergent Biosolutions	-40.16%	-0.43%	-0.15%
Amylyx Pharmaceuticals	N/A	-41.54%	-38.91%

Insider and Institutional Ownership

78.4% of Emergent Biosolutions shares are owned by institutional investors. Comparatively, 95.8% of Amylyx Pharmaceuticals shares are owned by institutional investors. 6.0% of Emergent Biosolutions shares are owned by insiders. Comparatively, 10.9% of Amylyx Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Amylyx Pharmaceuticals beats Emergent Biosolutions on 8 of the 14 factors compared between the two stocks.

About Emergent Biosolutions

Emergent BioSolutions is a biopharmaceutical company focused on products that address public health threats and medical emergencies. Its portfolio includes vaccines and treatments for infectious diseases, opioid overdose and other health risks, with customers that include governments and healthcare providers. Products associated with the company include BioThrax, an anthrax vaccine; ACAM2000, a smallpox vaccine; and NARCAN, a naloxone nasal spray used to reverse opioid overdose. Emergent also provides contract development and manufacturing services for pharmaceutical and biotechnology organizations.

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx’s research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.